Targeting neuroinflammation and demyelination at the source

Neuroinflammation is a shared upstream driver of neuronal damage and degeneration across major central nervous system disorders, including multiple sclerosis, Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis, as well as peripheral neuropathies such as CIDP, Guillain-Barré syndrome, and diabetic neuropathy.

Sources: PubMed Central, WHO

Neurological conditions are the leading cause of poor health and disability worldwide, affecting more than 40% of the global population (over 3 billion people) and accounting for more than 11 million deaths each year.

The total health burden associated with neurological diseases has increased by 18% since 1990, with further growth expected as populations age. The economic impact is already substantial: global dementia-related costs reached $1.3 trillion in 2021 and are projected to rise to $2 trillion by 2030.

Source: PubMed Central, WHO

Most current treatments for neuroinflammatory and neurodegenerative diseases act by broadly suppressing immune activity and reducing inflammation. In conditions such as CIDP and multiple sclerosis, disease‑modifying therapies lower relapse rates but do not repair established myelin or axonal damage, leaving many patients with accumulating neurological deficits. In Alzheimer’s disease, Parkinson’s disease and ALS, available therapies are largely symptomatic and do not effectively halt chronic neuroinflammation or progressive neuronal loss. Across peripheral and central nervous system conditions, there remains a major unmet need for targeted neuro‑immune therapies that not only resolve harmful inflammation but also promote durable structural repair and functional recovery.

Source: Feigin et al., The Lancet Neurology, 2019

Temper Bio is rising to meet this challenge, targeting neuroinflammation and neurodegeneration at its source with first-in-class therapeutics.